Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond.
Bispecific antibodies
Monoclonal antibodies
Prostate cancer
Prostate-specific membrane antigen
Radionuclide
Targeted radionuclide therapy
Journal
European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
28
01
2021
accepted:
05
02
2021
pubmed:
3
3
2021
medline:
31
3
2022
entrez:
2
3
2021
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) is a clinically validated target for prostate cancer. A variety of PSMA-based therapies, including radionuclide- and cytotoxic drug-conjugated and cellular immune products, are in development, each with variable advantages and disadvantages. Here we briefly describe the landscape of PSMA-based therapies beyond
Identifiants
pubmed: 33648895
pii: S2405-4569(21)00049-3
doi: 10.1016/j.euf.2021.02.006
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
254-257Informations de copyright
Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.